Phase I/IIa dose expansion study of Tegavivint in patients with Desmoid Tumors
Latest Information Update: 06 Jun 2021
At a glance
- Drugs Tegavivint (Primary)
- Indications Fibroma
- Focus Proof of concept; Therapeutic Use
- 13 Apr 2021 Results presented in an Iterion Therapeutics media release.
- 13 Apr 2021 According to an Iterion Therapeutics media release, the company continues to follow the patients that are still receiving treatment and look forward to sharing efficacy results at an upcoming medical conference.
- 13 Apr 2021 According to an Iterion Therapeutics media release, the final patient has been dosed in this trial.